检索结果-南通市图书馆

Ferroptosis:a critical mechanism of N^(6)-methyladenosine modification involved in carcinogenesis and tumor progression

引用

Science China(Life Sciences) 2024年第6期67卷 1119-1132页

作者： Qingqing Wei Changning Xue Mengna Li Jianxia Wei Lemei Zheng Shipeng Chen Yumei Duan Hongyu Deng Faqing Tang Wei Xiong Ming Zhou nhc key laboratory of carcinogenesis Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangsha 410013China cancer Research Institute and School of Basic Medical Sciences Central South UniversityChangsha 410078China The key laboratory of carcinogenesis and cancer Invasion of the Chinese Ministry of Education Central South UniversityChangsha 410078China hunan key laboratory of Oncotarget Gene Hunan Key Laboratory of Cancer MetabolismHunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangsha 410013China

Ferroptosis is an iron-dependent regulatory cell necrosis induced by iron overload and lipid peroxidation.It occurs when multiple redoxactive enzymes are ectopically expressed or show abnormal function.Hence,the precise regulation of ferroptosis-related molecules is mediated across multiple levels,including transcriptional,posttranscriptional,translational,and epigenetic levels.N^(6)-methyladenosine(m^(6)A)is a highly evolutionarily conserved epigenetic modification in mammals.The m^(6)A modification is commonly linked to tumor proliferation,progression,and therapy resistance because it is involved in RNA metabolic processes.Intriguingly,accumulating evidence suggests that dysregulated ferroptosis caused by the m^(6)A modification drives tumor development.In this review,we summarized the roles of m^(6)A regulators in ferroptosis-mediated malignant tumor progression and outlined the m^(6)A regulatory mechanism involved in ferroptosis pathways.We also analyzed the potential value and application strategies of targeting m^(6)A/ferroptosis pathway in the clinical diagnosis and therapy of tumors.

关键词： ferroptosis m6A modification RNA methylation m^(6)A regulator tumor progression

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Chronic stress as an emerging risk factor for the development and progression of glioma

引用

Chinese Medical Journal 2024年第4期137卷 394-407页

作者： Lan Yi Xiang Lin Xiaoling She Wei Gao Minghua Wu Institute of Cytology and Genetics The Hengyang Key Laboratory of Cellular Stress BiologyHunan Province Cooperative Innovation Center for Molecular Target New Drug StudyHengyang Medical SchoolUniversity of South ChinaHengyangHunan 421001China Department of Pathology The Second Xiangya HospitalCentral South UniversityChangshaHunan 410011China key laboratory of carcinogenesis and cancer Invasion of Ministry of Education Cancer Research InstituteCentral South UniversityChangshaHunan 410008China nhc key laboratory of carcinogenesis Xiangya HospitalCentral South UniversityChangshaHunan 410008China

Gliomas tend to have a poor prognosis and are the most common primary malignant tumors of the central nervous system.Compared with patients with other cancers,glioma patients often suffer from increased levels of psychological stress,such as anxiety and fear.Chronic stress(CS)is thought to impact glioma profoundly.However,because of the complex mechanisms underlying CS and variability in individual tolerance,the role of CS in glioma remains unclear.This review suggests a new proposal to redivide the stress system into two parts.Neuronal activity is dominant upstream.Stress-signaling molecules produced by the neuroendocrine system are dominant downstream.We discuss the underlying molecular mechanisms by which CS impacts glioma.Potential pharmacological treatments are also summarized from the therapeutic perspective of CS.

关键词： Chronic stress Glioma Microbiota-gut-brain axis Neuroendocrine system Stress system Neural circuit

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Role of adhesion molecules in cancer and targeted therapy

引用

Science China(Life Sciences) 2024年第5期67卷 940-957页

作者： Chunmei Fan Fang Xiong Shanshan Zhang Zhaojian Gong Qianjin Liao Guiyuan Li Can Guo Wei Xiong He Huang Zhaoyang Zeng nhc key laboratory of carcinogenesis and hunan key laboratory of cancer metabolism Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangsha 410000China Department of Histology and Embryology Xiangya School of MedicineCentral South UniversityChangsha410013China Department of Stomatology Xiangya HospitalCentral South UniversityChangsha 410078China Department of Oral and Maxillofacial Surgery The Second Xiangya HospitalCentral South UniversityChangsha 410011China key laboratory of carcinogenesis and cancer Invasion of the Chinese Ministry of Education Cancer Research InstituteCentral South UniversityChangsha 410078China

Adhesion molecules mediate cell-to-cell and cell-to-extracellular matrix interactions and transmit mechanical and chemical signals among them.Various mechanisms deregulate adhesion molecules in cancer,enabling tumor cells to proliferate without restraint,invade through tissue boundaries,escape from immune surveillance,and survive in the tumor microenvironment.Recent studies have revealed that adhesion molecules also drive angiogenesis,reshape metabolism,and are involved in stem cell self-renewal.In this review,we summarize the functions and mechanisms of adhesion molecules in cancer and the tumor microenvironment,as well as the therapeutic strategies targeting adhesion molecules.These studies have implications for furthering our understanding of adhesion molecules in cancer and providing a paradigm for exploring novel therapeutic approaches.

关键词： adhesion molecules tumor microenvironment invasion and metastasis reshaping metabolism angiogenesis immune evasion tumor stemness therapeutic strategy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Ferroptosis: a critical mechanism of N-methyladenosine modification involved in carcinogenesis and tumor progression

引用

Science China Life Sciences 2024年

作者： Qingqing Wei Changning Xue Mengna Li Jianxia Wei Lemei Zheng Shipeng Chen Yumei Duan Hongyu Deng Faqing Tang Wei Xiong Ming Zhou nhc key laboratory of carcinogenesis Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University The key laboratory of carcinogenesis and cancer Invasion of the Chinese Ministry of Education Central South University hunan key laboratory of Oncotarget Gene Hunan Key Laboratory of Cancer Metabolism Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine Central South University cancer Research Institute and School of Basic Medical Sciences Central South University

Ferroptosis is an iron-dependent regulatory cell necrosis induced by iron overload and lipid peroxidation. It occurs when multiple redoxactive enzymes are ectopically expressed or show abnormal function. Hence, the precise regulation of ferroptosis-related molecules is mediated across multiple levels, including transcriptional, posttranscriptional, translational, and epigenetic levels. N6-methyladenosine(m6A) is a highly evolutionarily conserved epigenetic modification in mammals. The m6A modification is commonly linked to tumor proliferation, progression, and therapy resistance because it is involved in RNA metabolic processes. Intriguingly, accumulating evidence suggests that dysregulated ferroptosis caused by the m6A modification drives tumor development. In this review, we summarized the roles of m6A regulators in ferroptosis-mediated malignant tumor progression and outlined the m6A regulatory mechanism involved in ferroptosis pathways. We also analyzed the potential value and application strategies of targeting m6A/ferroptosis pathway in the clinical diagnosis and therapy of tumors.

关键词：

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors

引用

Chinese Journal of cancer Research 2024年第3期36卷 257-276页

作者： Jian Li Ye Xu Aimin Zang Yunong Gao Quanli Gao Yanqiao Zhang Dong Wang Jianming Xu Ying Yuan Haiping Jiang Jieer Ying Chunmei Shi Yanhong Deng Jing Wang Tianshu Liu Yi Huang Xiaoping Qian Yueyin Pan Ying Cheng Sheng Hu Jin Wang Mengyue Shi Ke Wang Han Hu Lin Shen Department of Medical Oncology the First Affiliated Hospital Zhejiang University School of Medicine Department of Medical Oncology Cancer Hospital of the University of Chinese Academy of Sciences Department of Medical Oncology Fujian Medical University Union Hospital Department of Oncology the Sixth Affiliated Hospital Sun Yat-sen University Department of Medical Oncology Hunan Cancer Hospital Department of Medical Oncology Zhongshan HospitalFudan University Department of Immunotherapy Hubei Cancer Hospital Department of Medical Oncology the Affiliated Hospital of Nanjing University Medical School Department of Medical Oncology Anhui Provincial Hospital Department of Medical Oncology Jilin Cancer Hospital State key laboratory of Holistic Integrative Management of Gastrointestinal cancers Beijing Key Laboratory of Carcinogenesis and Translational Research Department of Gastrointestinal Oncology Peking University Cancer Hospital&Institute Department of Medical Oncology Hubei Cancer Hospital Clinical Development BeiGene(Shanghai)Co. Ltd. Biostatistics BeiGene(Beijing)Co. Ltd. Department of Oncology Fudan University Shanghai Cancer Center Department of Medical Oncology Affiliated Hospital of Hebei University key laboratory of carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Gynecology Peking University Cancer Hospital&Institute Department of Immunotherapy Henan Cancer Hospital Department of Gastrointestinal Oncology Affiliated Cancer Hospital of Harbin Medical University Department of Gastrointestinal Oncology Chongqing University Cancer Hospital Department of Gastrointestinal Oncology the Fifth Medical Center Chinese PLA General Hospital Department of Medical Oncology the Second Affiliated Hospital Zhejiang University School of Medicine

Objective: The open-label, phase Ⅱ RATIONALE-209 study evaluated tislelizumab(anti-programmed cell death protein 1 antibody) as a tissue-agnostic monotherapy for microsatellite instability-high(MSI-H)/mismatch repair-deficient(dMMR) tumors.Methods: Adults with previously treated, locally advanced unresectable or metastatic MSI-H/dMMR solid tumors were enrolled. Patients received tislelizumab 200 mg intravenously every 3 weeks. Objective response rate(ORR; primary endpoint), duration of response(DoR), and progression-free survival(PFS) were assessed by independent review committee(Response Evaluation Criteria in Solid Tumors v1.1).Results: Eighty patients were enrolled and treated; 75(93.8%) patients had measurable disease at baseline. Most had metastatic disease and received at least one prior therapy for advanced/metastatic disease(n=79; 98.8%). At primary analysis(data cutoff July 8, 2021; median follow-up 15.2 months), overall ORR [46.7%; 95% confidence interval(95% CI), 35.1-58.6; one-sided P<0.0001] and ORR across tumor-specific subgroups [colorectal(n=46):39.1%(95% CI, 25.1–54.6); gastric/gastroesophageal junction(n=9): 55.6%(95% CI, 21.2-86.3); others(n=20):60.0%(95% CI, 36.1-80.9)] were significantly greater with tislelizumab vs. a prespecified historical control ORR of 10%; five(6.7%) patients had complete responses. Median DoR, PFS, and overall survival were not reached with long-term follow-up(data cutoff December 5, 2022; median follow-up 28.9 months). Tislelizumab was well tolerated with no unexpected safety signals. Treatment-related adverse events(TRAEs) of grade ≥3 occurred in 53.8% of patients; 7.5% of patients discontinued treatment due to TRAEs.Conclusions: Tislelizumab demonstrated a significant ORR improvement in patients with previously treated,locally advanced unresectable or metastatic MSI-H/dMMR tumors and was generally well tolerated.

关键词： Biomarkers DNA mismatch repair immune checkpoint inhibitors microsatellite instability phase II clinical trials programmed cell death 1 receptor

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Effects of radiation therapy on tumor microenvironment:an updated review

引用

Chinese Medical Journal 2023年第23期136卷 2802-2811页

作者： Zewen Zhang Yuanhao Peng Xin Peng Desheng Xiao Ying Shi Yongguang Tao nhc key laboratory of carcinogenesis Cancer Research InstituteCentral South UniversityChangshaHunan 410078China Department of Pathology Key Laboratory of Carcinogenesis and Cancer InvasionMinistry of EducationSchool of Basic MedicineCentral South UniversityChangshaHunan 410078China hunan key laboratory of cancer metabolism Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangshaHunan 410078China Department of Thoracic Surgery Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung CancerSecond Xiangya HospitalCentral South UniversityChangshaHunan 410011China

cancer is a major threat to human health and causes death worldwide.Research on the role of radiotherapy(RT)in the treatment of cancer is progressing;however,RT not only causes fatal DNA damage to tumor cells,but also affects the interactions between tumor cells and different components of the tumor microenvironment(TME),including immune cells,fibroblasts,macrophages,extracellular matrix,and some soluble products.Some cancer cells can survive radiation and have shown strong resistance to radiation through interaction with the TME.Currently,the complex relationships between the tumor cells and cellular components that play major roles in various TMEs are poorly understood.This review explores the relationship between RT and cell-cell communication in the TME from the perspective of immunity and hypoxia and aims to identify new RT biomarkers and treatment methods in lung cancer to improve the current status of unstable RT effect and provide a theoretical basis for further lung cancer RT sensitization research in the future.

关键词： Radiotherapy Tumor microenvironment Immune regulation Hypoxia

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Leucine-rich repeats containing 4 protein(LRRC4)in memory,psychoneurosis,and glioblastoma

引用

Chinese Medical Journal 2023年第1期136卷 4-12页

作者： Kun Deng Minghua Wu hunan cancer Hospital and The Affiliated cancer Hospital of Xiangya School of Medicine Central South UniversityChangshaHunan 410013China nhc key laboratory of carcinogenesis Xiangya HospitalCentral South UniversityChangshaHunan 410008China key laboratory of carcinogenesis and cancer Invasion of Ministry of Education Cancer Research InstituteCentral South UniversityChangshaHunan 410008China

Leucine-rich repeats containing 4(LRRC4,also named netrin-G ligand 2[NGL-2])is a member of the NetrinGs ligands(NGLs)family.As a gene with relatively high and specific expression in brain,it is a member of the leucine-rich repeat superfamily and has been proven to be a suppressor gene for gliomas,thus being involved in gliomagenesis.LRRC4 is the core of microRNA-dependent multi-phase regulatory loops that inhibit the proliferation and invasion of glioblastoma(GB)cells,including LRRC4/NGL2-activator protein 2(AP2)-microRNA(miR)182-LRRC4 and LRRC4-miR185-DNA methyltransferase 1(DNMT1)-LRRC4/specific protein 1(SP1)-DNMT1-LRRC4.In this review,we demonstrated LRRC4 as a new member of the partitioning-defective protein(PAR)polarity complex that promotes axon differentiation,mediates the formation and plasticity of synapses,and assists information input to the hippocampus and storage of memory.As an important synapse regulator,aberrant expression of LRRC4 has been detected in autism,spinal injury and GBs.LRRC4 is a candidate susceptibility gene for autism and a neuro-protective factor in spinal nerve damage.In GBs,LRRC4 is a novel inhibitor of autophagy,and an inhibitor of protein–protein interactions involving in temozolomide resistance,tumor immune microenvironment,and formation of circular RNA.

关键词： Netrin G Excitatory synapses Long-term potentiation Autism Multiple sclerosis Glioblastoma

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Overview and countermeasures of cancer burden in China

引用

Science China(Life Sciences) 2023年第11期66卷 2515-2526页

作者： Yian Wang Qijia Yan Chunmei Fan Yongzhen Mo Yumin Wang Xiayu Li Qianjin Liao Can Guo Guiyuan Li Zhaoyang Zeng Wei Xiong He Huang nhc key laboratory of carcinogenesis and hunan key laboratory of cancer metabolism Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangsha 410078China key laboratory of carcinogenesis and cancer Invasion of the Chinese Ministry of Education Cancer Research InstituteCentral South UniversityChangsha 410078China hunan key laboratory of Nonresolving Inflammation and cancer Disease Genome Research CenterThe Third Xiangya HospitalCentral South UniversityChangsha 410078China Department of Otolaryngology Head and Neck Surgery Xiangya HospitalCentral South UniversityChangsha 410078China

cancer is one of the leading causes of human death worldwide.Treatment of cancer exhausts significant medical resources,and the morbidity and mortality caused by cancer is a huge social burden.cancer has therefore become a serious economic and social problem shared globally.As an increasingly prevalent disease in China,cancer is a huge challenge for the country’s healthcare system.Based on recent data published in the Journal of the National cancer Center on cancer incidence and mortality in China in 2016,we analyzed the current trends in cancer incidence and changes in cancer mortality and survival rate in China.And also,we examined several key risk factors for cancer pathogenesis and discussed potential countermeasures for cancer prevention and treatment in China.

关键词： cancer incidence mortality survival statistics countermeasures China

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

YWHAH activates the HMGA1/PI3K/AKT/mTOR signaling pathway by positively regulating Fra-1 to affect the proliferation of gastric cancer cells

引用

Oncology Research 2023年第4期31卷 615-630页

作者： JUNYU HE FENG ZENG XI JIN LIN LIANG MENGXIANG GAO WENTAO LI GUIYUAN LI YANHONG ZHOU nhc key laboratory of carcinogenesis Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangsha410013China cancer Research Institute Basic School of MedicineCentral South UniversityChangsha410078China hunan key laboratory of cancer metabolism Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangsha410013China

Fos-related antigen 1(Fra-1)is a nuclear transcription factor that regulates cell growth,differentiation,and apoptosis.It is involved in the proliferation,invasion,apoptosis and epithelial mesenchymal transformation of malignant tumor cells.Fra-1 is highly expressed in gastric cancer(GC),affects the cycle distribution and apoptosis of GC cells,and participates in GC occurrence and development.However,the detailed mechanism of Fra-1 in GC is unclear,such as the identification of Fra-1-interacting proteins and their role in GC pathogenesis.In this study,we identified tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta(YWHAH)as a Fra-1-interacting protein in GC cells using co-immunoprecipitation combined with liquid chromatography-tandem mass spectrometry.Experiments showed that YWHAH positively regulated Fra-1 mRNA and protein expression,and affected GC cell proliferation.Whole proteome analysis showed that Fra-1 affected the activity of the high mobility group AT-hook 1(HMGA1)/phosphatidylinositol-4,5-bisphosphate 3-kinase(PI3K)/protein kinase B(AKT)/mechanistic target of rapamycin(mTOR)signaling pathway in GC cells.Western blotting and flow cytometry confirmed that YWHAH activated HMGA1/PI3K/AKT/mTOR signaling pathway by positively regulating Fra-1 to affect GC cell proliferation.These results will help to discover new molecular targets for the early diagnosis,treatment,and prognosis prediction of GC.

关键词： Gastric cancer Fra-1 YWHAH Signal transduction pathway Cell proliferation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Immunometabolism:a new dimension in immunotherapy resistance

引用

Frontiers of Medicine 2023年第4期17卷 585-616页

作者： Chaoyue Xiao Wei Xiong Yiting Xu Ji’an Zou Yue Zeng Junqi Liu Yurong Peng Chunhong Hu Fang Wu Department of Oncology The Second Xiangya HospitalCentral South UniversityChangsha 410011China nhc key laboratory of carcinogenesis and key laboratory of carcinogenesis and cancer Invasion of the Chinese Ministry of Education Cancer Research InstituteCentral South UniversityChangsha 410078China Xiangya School of Medicine Central South UniversityChangsha 410013China hunan cancer Mega-Data Intelligent Application and Engineering Research Centre Changsha 410011China hunan key laboratory of Early Diagnosis and Precision Therapy in Lung cancer The Second Xiangya HospitalCentral South UniversityChangsha 410011China hunan key laboratory of Tumor Models and Individualized Medicine The Second Xiangya HospitalCentral South UniversityChangsha 410011China

Immune checkpoint inhibitors(ICIs)have demonstrated unparalleled clinical responses and revolutionized the paradigm of tumor treatment,while substantial patients remain unresponsive or develop resistance to ICIs as a single agent,which is traceable to cellular metabolic dysfunction.Although dysregulated metabolism has long been adjudged as a hallmark of tumor,it is now increasingly accepted that metabolic reprogramming is not exclusive to tumor cells but is also characteristic of immunocytes.Correspondingly,people used to pay more attention to the effect of tumor cell metabolism on immunocytes,but in practice immunocytes interact intimately with their own metabolic function in a way that has never been realized before during their activation and differentiation,which opens up a whole new frontier called immunometabolism.The metabolic intervention for tumor-infiltrating immunocytes could offer fresh opportunities to break the resistance and ameliorate existing ICI immunotherapy,whose crux might be to ascertain synergistic combinations of metabolic intervention with ICIs to reap synergic benefits and facilitate an adjusted anti-tumor immune response.Herein,we elaborate potential mechanisms underlying immunotherapy resistance from a novel dimension of metabolic reprogramming in diverse tumor-infiltrating immunocytes,and related metabolic intervention in the hope of offering a reference for targeting metabolic vulnerabilities to circumvent immunotherapeutic resistance.

关键词： immune cell immunometabolism metabolic reprogramming immunotherapy resistance tumor microenvironment immune checkpoint inhibitor

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：